# US 2023/0065640 A1 · Combination therapies and biomarkers for treating b-cell lymphomas

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065640 A1
- Document ID: US20230065640A1
- Status: Published application
- Kind: A1
- Application number: 17/797,621
- Filed: 2021-02-05
- Published: 2023-03-02
- Earliest claimed: 2020-02-07
- Inventors: Xiang LI; Yiyou CHEN
- Web page: https://patentgrep.com/patent/US20230065640A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/2887: {against CD20}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided are combination therapies and secondary biomarkers for treating MYCC-associated diffuse large B-cell lymphoma (DLBCL) with YM155-based therapies, and related kits, compositions, and methods of use thereof.

## Claims

### Claim 1

A method for treating a MYCC-associated diffuse large B-cell lymphoma (DLBCL) in a subject in need thereof, comprising
administering YM155 monobromide [1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide], or an analog or derivative thereof,
thereby treating the MYCC-associated DLBCL in the subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, comprising,
(a) determining MYCC gene copy number, or MYCC gene chromosomal location site, in a DLBCL sample from the subject; and
(b) administering YM155 monobromide [1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide], or an analog or derivative thereof, to the subject if MYCC gene copy number in the DLBCL sample is increased relative to that of a MYCC gene copy number reference, or if MYCC gene chromosomal location site in the DLBCL sample is translocated relative to that of a MYCC gene chromosomal location site reference.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, comprising administering to the subject a chemotherapeutic agent excluding (or other than) YM155 monobromide if MYCC gene copy number in the DLBCL sample is not substantially increased relative to that of the MYCC gene copy number reference, or if MYCC gene chromosomal location site in the DLBCL sample is not translocated relative to that of the MYCC gene chromosomal location site reference.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, comprising administering YM155, or an analog or derivative thereof, to the subject in combination with a second anti-cancer agent selected from CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), an anti-CD20 antibody, bendamustine, and an PARP inhibitor, including combinations thereof, optionally R-CHOP (ritixumab+CHOP).

### Claim 5 (depends on 4)

The method of claim 4, wherein the anti-CD20 antibody is selected from one or more of rituximab, ofatumumab, ocrelizumab, Iodine-131 tositumomab, obinutuzumab, and ibritumomab, or wherein the PARP inhibitor is selected from one or more of olaparib, rucaparib, nirparib, talazoparib, talazoparib, veliparib, and pamiparib.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the MYCC gene copy number in the DLBCL sample is increased by about or at least about 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10-fold relative to that of the MYCC gene copy number reference.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, comprising determining MYCC gene copy number in the DLBCL sample by array comparative genome hybridization (aCGH), single nucleotide polymorphism (SNP) array, copy number variation (CNV) sequencing, or multiplex ligation-dependent probe amplification (MLPA).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, comprising determining MYCC gene chromosomal location site in the DLBCL sample by in situ hybridization (ISH), fluorescence in situ hybridization (FISH), next generation sequencing (NGS), or comparative genome hybridization (CGH).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, comprising obtaining the MYCC gene copy number reference from a database, or determining the MYCC gene copy number reference from a non-cancerous tissue (optionally B-cell) from a control, optionally by aCGH, SNP array, CNV sequence, or MLPA.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, comprising obtaining the MYCC gene chromosomal location site reference from a database, or determining the MYCC gene chromosomal location site reference from a non-cancerous tissue (optionally B-cell) from a control, optionally by ISH, FISH, NGS, or CGH.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, comprising obtaining the DLBCL sample from the subject.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the DLBCL sample is a surgical sample, a biopsy sample, a pleural effusion sample, or an ascetic fluid sample obtained from the subject, optionally selected from one or more of blood, lymph node, and bone marrow.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the subject is a human subject.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the DLBCL is selected from DLBCL not otherwise specified (DLBCL-NOS), T-cell/histiocyte-rich B-cell lymphoma, primary or secondary DLBCL of the central nervous system (CNS), primary cutaneous DLBCL (leg type), and Epstein-Barr virus (EBV)-positive DLBCL optionally of the elderly.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the DLBCL is refractory to prior therapy, optionally selected from anthracycline-based therapy, CHOP, anti-CD20 therapy (optionally rituximab), R-CHOP (ritixumab+CHOP), radiation therapy, etoposide (optionally R-EPOCH), and autologous stem cell transplant (ASCT), including combinations thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the DLBCL expresses or overexpresses BCL2, BCL6, or both, and/or wherein the DLBCL comprises an alteration of the BCL2 gene (18q21 locus), an alteration of the BCL-6 gene (3q27 locus), or both.

### Claim 17 (depends on 16)

The method of claim 16, further comprising,
(c) determining BCL2 and/or BCL6 expression in the DLBCL sample from the subject, and/or determining alterations of the BCL2 gene (18q21 locus) and/or the BCL6 gene (3q27 locus) in the DLBCL sample from the subject.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, further comprising administering a second anti-cancer agent comprising a BCL2 inhibitor to the subject if the DLBCL expresses or overexpresses BCL2, and/or if the DLBCL comprises an alteration of the BCL2 gene (18q21 locus), optionally wherein the BCL2 inhibitor is selected from ABT199 (venetoclax), ABT-263 (navitoclax), ABT-737, GX-15-070 (obatoclax), GDC-0199, BP1002 (antisense), AT-101, and SPC2996.

### Claim 19 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 4-18, wherein the YM155 monobromide, or the analog or derivative thereof, and the second anti-cancer agent are administered separately or sequentially.

### Claim 20 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 4-18, wherein the YM155 monobromide, or the analog or derivative thereof, and the second anti-cancer agent are administered together at the same time.

### Claim 21

A method for treating a MYCC/BCL2-associated diffuse large B-cell lymphoma (DLBCL) in a subject in need thereof, comprising
administering YM155 monobromide [1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide], or an analog or derivative thereof,
thereby treating the MYCC/BCL2-associated DLBCL in the subject in need thereof.

### Claim 22 (depends on 21)

The method of claim 21, comprising
(a) determining MYCC gene copy number, or MYCC gene chromosomal location site, in the DLBCL sample from the subject;
(b) determining BCL2 expression in the DLBCL sample from the subject, and/or determining alterations of the BCL2 gene (18q21 locus) in the DLBCL sample from the subject; and
(c) administering YM155 monobromide [1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide], or an analog or derivative thereof, to the subject if MYCC gene copy number in the DLBCL sample is increased relative to that of a MYCC gene copy number reference, or if MYCC gene chromosomal location site in the DLBCL sample is translocated relative to that of a MYCC gene chromosomal location site reference, and if the DLBCL expresses or overexpresses BCL2, and/or if the DLBCL comprises an alteration of the BCL2 gene (18q21 locus).

### Claim 23 (depends on 21, 22)

The method of claim 21 or 22, comprising administering YM155, or an analog or derivative thereof, to the subject in combination with a second anti-cancer agent selected from a BCL2 inhibitor, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), an anti-CD20 antibody, bendamustine, and an PARP inhibitor, including combinations thereof, optionally R-CHOP (ritixumab+CHOP).

### Claim 24 (depends on 23)

The method of claim 23, wherein the BCL2 inhibitor is selected from ABT199 (venetoclax), ABT-263 (navitoclax), ABT-737, GX-15-070 (obatoclax), GDC-0199, BP1002 (antisense), AT-101, and SPC2996.

### Claim 25 (depends on 23)

The method of claim 23, wherein the anti-CD20 antibody is selected from one or more of rituximab, ofatumumab, ocrelizumab, Iodine-131 tositumomab, obinutuzumab, and ibritumomab, or wherein the PARP inhibitor is selected from one or more of olaparib, rucaparib, nirparib, talazoparib, talazoparib, veliparib, and pamiparib.

### Claim 26 (depends on 21, 22, 23, 24, 25)

The method of any one of claims 21-25, wherein the MYCC gene copy number in the DLBCL sample is increased by about or at least about 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10-fold relative to that of the MYCC gene copy number reference.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21-26, comprising determining MYCC gene copy number in the DLBCL sample by array comparative genome hybridization (aCGH), single nucleotide polymorphism (SNP) array, copy number variation (CNV) sequencing, or multiplex ligation-dependent probe amplification (MLPA).

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 21-27, comprising determining MYCC gene chromosomal location site in the DLBCL sample by in situ hybridization (ISH), fluorescence in situ hybridization (FISH), next generation sequencing (NGS), or comparative genome hybridization (CGH).

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 21-28, comprising obtaining the MYCC gene copy number reference from a database, or determining the MYCC gene copy number reference from a non-cancerous tissue (optionally B-cell) from a control, optionally by aCGH, SNP array, CNV sequence, or MLPA.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 21-29, comprising obtaining the MYCC gene chromosomal location site reference from a database, or determining the MYCC gene chromosomal location site reference from a non-cancerous tissue (optionally B-cell) from a control, optionally by ISH, FISH, NGS, or CGH.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 21-30, comprising obtaining the DLBCL sample from the subject.

### Claim 32 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 21-31, wherein the DLBCL sample is a surgical sample, a biopsy sample, a pleural effusion sample, or an ascetic fluid sample obtained from the subject, optionally selected from one or more of blood, lymph node, and bone marrow.

### Claim 33 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 21-32, wherein the subject is a human subject.

### Claim 34 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 21-33, wherein the DLBCL is selected from DLBCL not otherwise specified (DLBCL-NOS), T-cell/histiocyte-rich B-cell lymphoma, primary or secondary DLBCL of the central nervous system (CNS), primary cutaneous DLBCL (leg type), and Epstein-Barr virus (EBV)-positive DLBCL optionally of the elderly.

### Claim 35 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 21-34, wherein the DLBCL is refractory to prior therapy, optionally selected from anthracycline-based therapy, CHOP, anti-CD20 therapy (optionally rituximab), R-CHOP (ritixumab+CHOP), radiation therapy, etoposide (optionally R-EPOCH), and autologous stem cell transplant (ASCT), including combinations thereof.

### Claim 36

A patient care kit, comprising:
(a) means for measuring MYCC gene copy number, or MYCC gene chromosomal location site, in a diffuse large B-cell lymphoma (DLBCL) sample of tissue from a subject, including cancer tissue and non-cancerous tissue;
(b) YM155 monobromide [1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide], or an analog or derivative thereof; and
(c) a second anti-cancer agent selected from CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), an anti-CD20 antibody, bendamustine, a PARP inhibitor, and a BCL2 inhibitor, including combinations thereof, optionally R-CHOP (ritixumab+CHOP).

### Claim 37 (depends on 36)

The patient care kit of claim 36, wherein the anti-CD20 antibody is selected from one or more of rituximab, ofatumumab, ocrelizumab, Iodine-131 tositumomab, obinutuzumab, and ibritumomab, or wherein the PARP inhibitor is selected from one or more of olaparib, rucaparib, nirparib, talazoparib, talazoparib, veliparib, and pamiparib, or wherein the BCL2 inhibitor is selected from ABT199 (venetoclax), ABT-263 (navitoclax), ABT-737, GX-15-070 (obatoclax), GDC-0199, BP1002 (antisense), AT-101, and SPC2996.

### Claim 38 (depends on 36, 37)

The patient care kit of claim 36 or 37, wherein the means for measuring MYCC gene copy number comprise reagents for performing a diagnostic assay selected from one or more of array comparative genome hybridization (aCGH), single nucleotide polymorphism (SNP) array, copy number variation (CNV) sequencing, and multiplex ligation-dependent probe amplification (MLPA) on a human MYCC gene.

### Claim 39 (depends on 36, 37, 38)

The patient care kit of any one of claims 36-38, wherein the means for measuring MYCC gene chromosomal location site comprise reagents for performing a diagnostic assay selected from one or more of in situ hybridization (ISH), fluorescence in situ hybridization (FISH), next generation sequencing (NGS), and comparative genome hybridization (CGH) on a human MYCC gene.

### Claim 40 (depends on 36, 37, 38, 39)

The patient care kit of any one of claims 36-39, comprising a MYCC gene copy number reference value obtained from a database, or determined from a non-cancerous tissue from a control.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The patient care kit of any one of claims 36-40, comprising a MYCC gene chromosomal location site reference obtained from a database, or determined from a non-cancerous tissue from a control.

### Claim 42 (depends on 36, 37, 38, 39, 40, 41)

The patient care kit of any one of claims 36-41, comprising (d) means for determining BCL2 expression in the sample of tissue from the subject, and/or means for determining alterations of the BCL2 gene (18q21 locus) in the sample of tissue from the subject.

### Claim 43

A patient care kit, comprising:
(a) means for measuring MYCC gene copy number, or MYCC gene chromosomal location site, in a diffuse large B-cell lymphoma (DLBCL) sample of tissue from a subject, including cancer tissue and non-cancerous tissue;
(b) means for determining BCL2 expression in the DLBCL sample of tissue from the subject, and/or means for determining alterations of the BCL2 gene (18q21 locus) in the sample of tissue from the subject; and
(c) YM155 monobromide [1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d] imidazolium bromide], or an analog or derivative thereof.

### Claim 44 (depends on 43)

The patient care kit of claim 43, comprising (d) a second anti-cancer agent selected from CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), an anti-CD20 antibody, bendamustine, a PARP inhibitor, and a BCL2 inhibitor, including combinations thereof, optionally R-CHOP (ritixumab+CHOP).

### Claim 45 (depends on 43, 44)

The patient care kit of claim 43 or 44, wherein the anti-CD20 antibody is selected from one or more of rituximab, ofatumumab, ocrelizumab, Iodine-131 tositumomab, obinutuzumab, and ibritumomab, or wherein the PARP inhibitor is selected from one or more of olaparib, rucaparib, nirparib, talazoparib, talazoparib, veliparib, and pamiparib, or wherein the BCL2 inhibitor is selected from ABT199 (venetoclax), ABT-263 (navitoclax), ABT-737, GX-15-070 (obatoclax), GDC-0199, BP1002 (antisense), AT-101, and SPC2996.

### Claim 46 (depends on 43, 44, 45)

The patient care kit of any one of claims 43-45, wherein the means for measuring MYCC gene copy number comprise reagents for performing a diagnostic assay selected from one or more of array comparative genome hybridization (aCGH), single nucleotide polymorphism (SNP) array, copy number variation (CNV) sequencing, and multiplex ligation-dependent probe amplification (MLPA) on a human MYCC gene.

### Claim 47 (depends on 43, 44, 45, 46)

The patient care kit of any one of claims 43-46, wherein the means for measuring MYCC gene chromosomal location site comprise reagents for performing a diagnostic assay selected from one or more of in situ hybridization (ISH), fluorescence in situ hybridization (FISH), next generation sequencing (NGS), and comparative genome hybridization (CGH) on a human MYCC gene

### Claim 48 (depends on 43, 44, 45, 46, 47)

The patient care kit of any one of claims 43-47, comprising a MYCC gene copy number reference value obtained from a database, or determined from a non-cancerous tissue from a control

### Claim 49 (depends on 43, 44, 45, 46, 47, 48)

The patient care kit of any one of claims 43-48, comprising a MYCC gene chromosomal location site reference obtained from a database, or determined from a non-cancerous tissue from a control.
